Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Charles Gordon

Interventional Pain Medicine Clifton Park, NY Medical Doctor

NPI 1649243890 CMS profile 29569

9 Old Plank Road, Suite 100, Clifton Park, NY 12065

Open in the dashboard

General payments

$15,055

325 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Charles Gordon of Clifton Park, NY is reported in the CMS Open Payments database as having received $15,055 across 325 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 81st percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,729 32
2024 General $1,024 32
2023 General $5,042 72
2022 General $2,010 50
2021 General $1,286 46
2020 General $1,459 39
2019 General $2,504 54

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Charles Gordon
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Charles Gordon were reported at $1,729. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Charles Gordon Interventional Pain Medicine median Middle half National median
2019 $2,504 $684 $216–$2,079 $163
2020 $1,459 $382 $122–$1,109 $114
2021 $1,286 $552 $167–$1,554 $132
2022 $2,010 $605 $187–$1,924 $149
2023 $5,042 $671 $195–$1,915 $160
2024 $1,024 $684 $206–$1,837 $164
2025 $1,729 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $11,039 246 payments
  2. Medtronic, Inc. $1,041 8 payments
  3. Vertos Medical, Inc. $664 11 payments
  4. Abbott Laboratories $460 10 payments
  5. SPR Therapeutics, Inc $414 10 payments
  6. Nevro Corp. $340 10 payments
  7. Nalu Medical, Inc. $266 2 payments
  8. Saluda Medical Americas, Inc. $179 1 payment
  9. Painteq LLC $125 1 payment
  10. AcelRx Pharmaceuticals, Inc. $113 2 payments
  11. Other $415 24 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $12,355 313 payments
  2. Travel and Lodging $2,700 12 payments
Products named General payments · program years 2019–2025
  1. WaveWriter Alpha Prime 16 $3,346 80 payments
  2. SPECTRA WAVEWRITER $2,075 34 payments
  3. KYPHON EXPRESS II KYPHOPAK TRAY $1,005 7 payments
  4. GENERAL PAIN MANAGEMENT $930 33 payments
  5. Superion Indirect Decompression System $728 4 payments
  6. mild Device Kit $664 11 payments
  7. General - Pain Management General - Pain Management_NMD $663 23 payments
  8. GENERAL - PAIN MANAGEMENT Pain Management $594 16 payments
  9. SPRINT PNS System $414 10 payments
  10. Senza Spinal Cord Stimulation System $298 8 payments
  11. Other $2,737 86 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

11

Median for Interventional Pain Management: 1,220

Drug cost

$272

Median for Interventional Pain Management: $39,344

Branded share of claims

0%

Median for Interventional Pain Management: 34.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 11 $272

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,476 Part D prescribers listed as Interventional Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 50 billing codes

Paid by Medicare

$224,360

Of which drugs: $3,419

Medicare patients

386

Average age 75

Services billed

4,453

200 women, 186 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 74%
Ischemic heart disease 35%
Diabetes 29%
Chronic kidney disease 24%
Depression 23%
Atrial fibrillation 18%
COPD 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 117 218 $162
Injection, midazolam hydrochloride, per 1 mg J2250 Office 19 42 $4

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

325 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record